Janssen-Cilag Ltd.
Clinical trials sponsored by Janssen-Cilag Ltd., explained in plain language.
A pharmaceutical company, subsidiary of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise for healing Crohn's fistulas Results expected Mar 2027 (estimated)
- Can this drug fully heal the gut in Crohn's? Results expected Jun 2027 (estimated)
-
Esketamine nasal Spray's Long-Term safety under the microscope
Disease control CompletedThis study looked at the long-term safety of esketamine nasal spray (a fast-acting antidepressant) when used together with standard antidepressants in 183 people with treatment-resistant depression. Participants had already completed 32 weeks of esketamine treatment and continued…
Phase 4 • Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:35 UTC
-
New Low-Dose pain patch aims to ease cancer suffering
Symptom relief CompletedThis study tested a low-dose fentanyl patch in 14 cancer patients in Taiwan to see if it is safe and tolerable for managing pain. The patch delivers pain medicine through the skin over 28 days. The main goal was to see how many patients dropped out due to side effects, with the h…
Phase 4 • Sponsor: Janssen-Cilag Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Real-World study compares two prostate cancer drug combos
Knowledge-focused CompletedThis study follows about 500 men with advanced prostate cancer that still responds to hormone therapy. Researchers are comparing two drug combinations (apalutamide or enzalutamide plus standard hormone therapy) to see how well they work in real-world settings. The goal is to unde…
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New study maps the path from smoldering to active myeloma
Knowledge-focused CompletedThis study reviewed medical records of 431 people with smoldering multiple myeloma (SMM), a pre-cancerous condition, to see how the disease progresses over time. Researchers looked at which patients are at higher risk of developing active multiple myeloma and what treatments they…
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC